A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Trial Profile

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Pegaspargase (Primary) ; Dexamethasone
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2017 Planned End Date changed from 1 Sep 2018 to 1 Feb 2018.
    • 10 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 03 Feb 2014 According to ClinicalTrials.gov record trial status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top